Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04201834 · ClinicalTrials.gov registry record · Phase 2
Risperidone for the Treatment of Huntington's Disease Involuntary Movements
A Phase 2 study, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT04201834 is a Phase 2 study that has completed, run by University of Rochester. The registered enrollment target is 6 participants.
The verdict
NCT04201834, a Phase 2 study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and benefit of risperidone for the treatment of chorea (involuntary movements) in Huntington's disease. Risperidone is commonly used in clinical practice to treat chorea, however, it has not been approved by the Food and Drug Administration (FDA) to treat chorea. This study will examine 1) whether the investigators see MRI changes with risperidone treatment and 2) whether sensors applied to the participants body can measure chorea and detect changes in chorea.
Interventions
- DRUG Risperidone
- DEVICE BioStamp nPoint device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2020-08-13 |
| Est. Completion | 2023-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04201834
The ClinicalTrials.gov registry entry for NCT04201834 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Risperidone is the first listed.
NCT04201834 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04201834 about?
NCT04201834 is a clinical study titled "Risperidone for the Treatment of Huntington's Disease Involuntary Movements". The purpose of this study is to assess the safety and benefit of risperidone for the treatment of chorea (involuntary movements) in Huntington's disease. Risperidone is commonly used in clinical practice to treat chorea, however, it has not been approved by the Food and Drug Administration (FDA) to ...
What is the current status of trial NCT04201834?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2020-08-13. Estimated completion is 2023-12-30.
What interventions are being tested in trial NCT04201834?
The interventions under investigation include: Risperidone (DRUG), BioStamp nPoint device (DEVICE).
Who is sponsoring clinical trial NCT04201834?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.